IP Library Granted Patent US 11,020,468
Granted Patent B2
US 11,020,468 · App. 16/574,202 · Granted Jun 1, 2021

Compositions, methods and therapies for administering antigen peptide

Inventors: Kenichiro Hasumi (Tokyo, JP); Mikio Kuraya (Tokyo, JP)
Assignee: Kenichiro Hasumi
A61K39/0208A61K31/7088A61K38/164A61K39/05A61K45/06C07K14/195C07K14/36A61K2039/53A61K2039/55516A61K2039/55588A61K2039/58A61K2039/645A61K2039/70C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,468
App. No.
16/574,202
Granted
Jun 1, 2021
Kind
B2
Abstract

The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes . The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.

Claims (9)

1. A composition to reduce inflammation in a patient with a Propionibacterium acnes infection, comprising:

a peptide consisting of the amino acid sequence of SEQ NO. 1;

a peptide consisting of the amino acid sequence of SEQ NO. 3; and

a TNF inhibitor.

2. The composition of claim 1 , wherein at least one of the peptide consisting of the amino acid sequence of SEQ NO. 1 and the peptide consisting of the amino acid sequence of SEQ NO. 3 is a multivalent antigen peptide obtained by binding a plurality of the peptide consisting of the amino acid sequence of SEQ NO. 1 or a plurality of the peptide consisting of the amino acid sequence of SEQ NO. 3 by a linker.

3. The composition of claim 1 , further comprising an adjuvant.

4. The composition of claim 3 , wherein the adjuvant is aluminum hydroxide.

5. The composition of claim 1 , wherein the TNF inhibitor further comprises a delivery mechanism selected from the group consisting of a liquid carrier and a medium.

6. The composition of claim 1 , wherein the composition is in the form of a solution.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2019
From: HASUMI, KENICHIRO; KURAYA, MIKIO
To: KENICHIRO HASUMI
Reel/Frame 050427/0224 →
Continuity (5)
Division 15863328 · Jan 5, 2018
Division 14312162 · Jun 23, 2014
Continuation In Part 13380425
Provisional Application 61396574 · May 27, 2010
Related Publication 20200009239A1 · Jan 9, 2020
Cited By (1)
US 12,502,424